The Canadian Immunization Research Network (CIRN) is an academic clinical research institution based in Halifax, Nova Scotia. It operates out of the Canadian Center for Vaccinology at the IWK Health Centre.[1]
The program operated as the PHAC/CIHR Influenza Research Network (PCIRN) from 2009-2014. It then relaunched as CIRN from June 2014–May 2017 with a three-year grant of $6.6 million from the Public Health Agency of Canada (PHAC) and the Canadian Institutes of Health Research (CIHR). A directed CIRN renewal grant application was submitted in February 2017. In April 2017, the network was notified that it was fully funded for $10,083,334 over the next 55 months, 2017-2022.[2]
CIRN has led a number of studies related to COVID-19 vaccines since 2020.
The CIRN is running the CANVAS-COVID trial through the Canadian National Vaccine Safety Network, which is a national platform that monitors vaccine safety after vaccines are approved for use.[3]
COVID-19 injection programs started in Canada in December 2020 with products from Pfizer-BioNTech, Moderna and AstraZeneca becoming available over the winter and into spring of 2021. In Canada, a strategy to deliver as many first doses as possible resulted in mixed brands (giving a different second COVID-19 dose to the first dose) and schedules (length of time between doses) being used in many parts of the country. This was in spite of no prior testing for safety or efficacy of mixing products.
The first mix-and-match study, called MOSAIC-1, began in June 2021 and is still ongoing at 7 clinical sites in Canada. 195 participants were enrolled and received either two doses or the second authorized COVID-19 dose. Assessment is ongoing.[4]
The second iteration of the study, MOSAIC-2, began in December 2021 to evaluate the safety, tolerability, and immune response of a third dose of a COVID-19 product authorized in Canada (either the Pfizer-BioNTech or Moderna mRNA products) in people who had two doses of COVID-19 injections at least six months prior.
The study is led by the Clinical Trials Network of the Canadian Immunization Network (CIRN) and funded by the COVID-19 Immunity Task Force. It is led by Joanne Langley and Manish Sadarangani.[5]
CIRN is partnered with and funded by:[6][7][8][9][10]
Contact Us. Canadian Immunization Research Network. Retrieved May 30, 2023, from https://web.archive.org/web/20230530144626/https://cirnetwork.ca/about-us/contact-us/ ↩︎
About Us. CIRN | Canadian Immunization Research Network. Retrieved December 22, 2021 from http://archive.today/2021.12.22-184322/https://cirnetwork.ca/about-us/ ↩︎
CANVAS-COVID Study Enrolment. CANVAS-COVID. Retrieved August 21, 2022, from http://archive.today/2022.08.21-040624/https://canvas-covid.ca/ ↩︎
MOSAIC. CIRN | Canadian Immunization Research Network. Retrieved December 23, 2021 from http://archive.today/2021.12.23-094150/https://cirnetwork.ca/mosaic/ ↩︎
MOSAIC. CIRN | Canadian Immunization Research Network. Retrieved December 23, 2021, from http://archive.today/2021.12.23-094808/https://cirnetwork.ca/research-study/mosaic/ ↩︎
Partners. Canadian Immunization Research Network. Retrieved November 26, 2021, from http://archive.today/2021.11.26-051324/https://cirnetwork.ca/about-us/partners/ ↩︎
Annual Report 2019-2020. (2021, August). Canadian Immunization Research Network. https://web.archive.org/web/20230328075033/https://cirnetwork.ca/wp-content/uploads/2021/08/AR.2019-20.Final_.pdf ↩︎
Annual Report 2015. Canadian Immunization Research Network. Retrieved December 22, 2021, from https://cirnetwork.ca/annual-reports/2015/mobile/index.html#p=24 ↩︎
Annual Report 2014. Canadian Immunization Research Network. Retrieved December 22, 2021, from https://cirnetwork.ca/annual-reports/2014/mobile/index.html#p=1 ↩︎
2013 Annual Report. PHAC/CIHR Influenza Research Network. Retrieved July 20, 2023, from https://web.archive.org/web/20230720161922/https://www.campfire.wiki/lib/exe/fetch.php?media=pcirn-annual-reportfinal-2013.pdf ↩︎